188181-42-2 | 5'-O-(Elaidoyl) 1-β-D-arabinofuranosylcytosine

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$28.00	$19.00
5mg	98%	in stock	$58.00	$40.00
10mg	98%	in stock	$82.00	$57.00
50mg	98%	in stock	$235.00	$164.00
100mg	98%	in stock	$395.00	$276.00

Description

• Catalog Number: AE97190
• Chemical Name: 5'-O-(Elaidoyl) 1-β-D-arabinofuranosylcytosine
• CAS Number: 188181-42-2
• Molecular Formula: C27H45N3O6
• Molecular Weight: 507.6627
• MDL Number: MFCD19443751
• SMILES: CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1ccc(nc1=O)N

Computed Properties

• Complexity: 754
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 19
• XLogP3: 5.7

Literature

• Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.

  Investigational new drugs 20121001

• Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

  British journal of haematology 20120901

• Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.

  Leukemia 20120701

• Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

  Leukemia research 20120401

• Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia.

  Expert opinion on investigational drugs 20111201

• A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.

  Cancer chemotherapy and pharmacology 20111101

• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  Current medicinal chemistry 20110101

• The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues.

  Nucleosides, nucleotides & nucleic acids 20100601

• Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.

  Nucleosides, nucleotides & nucleic acids 20100601

• Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.

  International journal of oncology 20100101

• Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study.

  Acta oncologica (Stockholm, Sweden) 20090101

• CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.

  British journal of haematology 20090101

• Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.

  Leukemia & lymphoma 20080401

• Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.

  Biochemical pharmacology 20040201